These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17072716)

  • 1. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
    Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
    Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-1α siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma.
    Liao HY; Wang GP; Gu LJ; Huang SH; Chen XL; Li Y; Cai SW
    Asian Pac J Cancer Prev; 2012; 13(2):473-7. PubMed ID: 22524809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
    Kim JH; Ajaz M; Lokshin A; Lee YJ
    Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p-Hydroxylcinnamaldehyde from cochinchinamomordica seed reverses resistance to TRAIL in human oesophageal squamous cell carcinoma via the activation of the p38 mitogen-activated protein kinase signalling pathway.
    Ma M; Zhang C; Xiang XH; Deng XQ; Dai SL; Wei SS; Zhang XM; Zhao LM; Liu YJ; Shan BE
    Biomed Pharmacother; 2020 Jan; 121():109611. PubMed ID: 31731196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
    Shamimi-Noori S; Yeow WS; Ziauddin MF; Xin H; Tran TL; Xie J; Loehfelm A; Patel P; Yang J; Schrump DS; Fang BL; Nguyen DM
    Cancer Gene Ther; 2008 Jun; 15(6):356-70. PubMed ID: 18309355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation.
    Ma Z; Fan C; Yang Y; Di S; Hu W; Li T; Zhu Y; Han J; Xin Z; Wu G; Zhao J; Li X; Yan X
    Sci Rep; 2016 Oct; 6():35196. PubMed ID: 27731378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
    Liu P; Mao H; Hou P
    Int J Gynecol Cancer; 2006; 16(2):538-48. PubMed ID: 16681723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
    Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
    BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE
    Pun IH; Chan D; Chan SH; Chung PY; Zhou YY; Law S; Lam AK; Chui CH; Chan AS; Lam KH; Tang JC
    Cancer Res Treat; 2017 Jan; 49(1):219-229. PubMed ID: 27456944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL; Zou WY; Song LH; Wei W
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    Wang F; Ding X; Wang T; Shan Z; Wang J; Wu S; Chi Y; Zhang Y; Lv Z; Wang L; Fan Q
    PLoS One; 2017; 12(4):e0174276. PubMed ID: 28406985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
    Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.
    Han L; Dai S; Li Z; Zhang C; Wei S; Zhao R; Zhang H; Zhao L; Shan B
    J Exp Clin Cancer Res; 2019 Dec; 38(1):501. PubMed ID: 31864387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma.
    Kojima H; Okumura T; Yamaguchi T; Miwa T; Shimada Y; Nagata T
    Int J Oncol; 2017 Jul; 51(1):49-62. PubMed ID: 28534989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.